MANGOCEUTICALS, INC. Files 8-K Report
Ticker: MGRX · Form: 8-K · Filed: Oct 1, 2024 · CIK: 1938046
| Field | Detail |
|---|---|
| Company | Mangoceuticals, INC. (MGRX) |
| Form Type | 8-K |
| Filed Date | Oct 1, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC Filing, Reporting
TL;DR
MANGOCEUTICALS, INC. filed an 8-K, mostly procedural stuff.
AI Summary
On October 1, 2024, MANGOCEUTICALS, INC. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events detailed in the provided text. The company is incorporated in Texas and its principal executive offices are located in Dallas.
Why It Matters
This 8-K filing indicates MANGOCEUTICALS, INC. is fulfilling its reporting obligations with the SEC, though the specific material events are not detailed in this excerpt.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report without immediate disclosure of significant negative events.
Key Numbers
- 001-41615 — SEC File Number (Identifies the company's filing with the SEC.)
- 87-3841292 — IRS Employer Identification No. (Company's tax identification number.)
- 75248 — ZIP Code (Postal code for the company's principal executive offices.)
Key Players & Entities
- MANGOCEUTICALS, INC. (company) — Registrant
- Texas (location) — State of incorporation
- Dallas (location) — City of principal executive offices
- October 1, 2024 (date) — Date of earliest event reported
FAQ
What specific 'Other Events' are being reported by MANGOCEUTICALS, INC. in this 8-K?
The provided text for the 8-K filing lists 'Other Events' as an item information but does not specify the details of these events.
What is the primary purpose of this 8-K filing for MANGOCEUTICALS, INC.?
The filing is a Current Report on Form 8-K, indicating it's to report information that the company has elected or is required to report on a current basis, including 'Other Events' and 'Financial Statements and Exhibits'.
When was this 8-K filing submitted?
The filing was submitted on October 1, 2024, which is also the date of the earliest event reported.
Where are MANGOCEUTICALS, INC.'s principal executive offices located?
The principal executive offices of MANGOCEUTICALS, INC. are located at 15110 N. Dallas Parkway, Suite 600, Dallas, Texas, 75248.
What is the company's state of incorporation?
MANGOCEUTICALS, INC. is incorporated in Texas.
Filing Stats: 849 words · 3 min read · ~3 pages · Grade level 12 · Accepted 2024-10-01 07:30:15
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 Par Value Per Share MGRX The Nasdaq
Filing Documents
- form8-k.htm (8-K) — 41KB
- ex99-1.htm (EX-99.1) — 21KB
- 0001493152-24-038933.txt ( ) — 244KB
- mgrx-20241001.xsd (EX-101.SCH) — 3KB
- mgrx-20241001_lab.xml (EX-101.LAB) — 33KB
- mgrx-20241001_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MANGOCEUTICALS, INC. Date: October 1, 2024 By: /s/ Jacob D. Cohen Jacob D. Cohen Chief Executive Officer